Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD163 inhibitors(Scavenger receptor cysteine-rich type 1 protein M130 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 01 May 2024 | |
Atherosclerosis | Preclinical | United States | 28 Mar 2024 |